479 related articles for article (PubMed ID: 22342714)
1. Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies.
Dümichen MJ; Seeger K; Lode HN; Kühl JS; Ebell W; Degenhardt P; Singer M; Geffers C; Querfeld U
J Hosp Infect; 2012 Apr; 80(4):304-9. PubMed ID: 22342714
[TBL] [Abstract][Full Text] [Related]
2. Biofilm formation in long-term central venous catheters in children with cancer: a randomized controlled open-labelled trial of taurolidine versus heparin.
Handrup MM; Fuursted K; Funch P; Møller JK; Schrøder H
APMIS; 2012 Oct; 120(10):794-801. PubMed ID: 22958287
[TBL] [Abstract][Full Text] [Related]
3. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution.
Betjes MG; van Agteren M
Nephrol Dial Transplant; 2004 Jun; 19(6):1546-51. PubMed ID: 14993498
[TBL] [Abstract][Full Text] [Related]
4. Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).
Gudiol C; Nicolae S; Royo-Cebrecos C; Aguilar-Guisado M; Montero I; Martín-Gandul C; Perayre M; Berbel D; Encuentra M; Arnan M; Cisneros-Herreros JM; Carratalà J
Trials; 2018 May; 19(1):264. PubMed ID: 29720244
[TBL] [Abstract][Full Text] [Related]
5. Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine line lock.
Chu HP; Brind J; Tomar R; Hill S
J Pediatr Gastroenterol Nutr; 2012 Oct; 55(4):403-7. PubMed ID: 22595973
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ML8-X10 (a prototype oil-in-water micro-emulsion based on a novel free fatty acid), taurolidine/citrate/heparin and vancomycin/heparin antimicrobial lock solutions in the eradication of biofilm-producing staphylococci from central venous catheters.
Luther MK; Mermel LA; LaPlante KL
J Antimicrob Chemother; 2014 Dec; 69(12):3263-7. PubMed ID: 25096074
[TBL] [Abstract][Full Text] [Related]
7. A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients.
Gudiol C; Arnan M; Aguilar-Guisado M; Royo-Cebrecos C; Sánchez-Ortega I; Montero I; Martín-Gandul C; Laporte-Amargós J; Albasanz-Puig A; Nicolae S; Perayre M; Berbel D; Tebe C; Riera J; Sureda A; Cisneros JM; Carratalà J
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712211
[TBL] [Abstract][Full Text] [Related]
8. Microbiocidal effects of various taurolidine containing catheter lock solutions.
Olthof ED; Nijland R; Gülich AF; Wanten GJ
Clin Nutr; 2015 Apr; 34(2):309-14. PubMed ID: 24861410
[TBL] [Abstract][Full Text] [Related]
9. A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis.
Solomon LR; Cheesbrough JS; Ebah L; Al-Sayed T; Heap M; Millband N; Waterhouse D; Mitra S; Curry A; Saxena R; Bhat R; Schulz M; Diggle P
Am J Kidney Dis; 2010 Jun; 55(6):1060-8. PubMed ID: 20207458
[TBL] [Abstract][Full Text] [Related]
10. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters.
Winnicki W; Herkner H; Lorenz M; Handisurya A; Kikić Ž; Bielesz B; Schairer B; Reiter T; Eskandary F; Sunder-Plassmann G; Sengoelge G
Kidney Int; 2018 Mar; 93(3):753-760. PubMed ID: 28890326
[TBL] [Abstract][Full Text] [Related]
11. Taurolidine-citrate-heparin lock reduces catheter-related bloodstream infections in intestinal failure patients dependent on home parenteral support: a randomized, placebo-controlled trial.
Tribler S; Brandt CF; Petersen AH; Petersen JH; Fuglsang KA; Staun M; Broebech P; Moser CE; Jeppesen PB
Am J Clin Nutr; 2017 Sep; 106(3):839-848. PubMed ID: 28793993
[No Abstract] [Full Text] [Related]
12. Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin.
Handrup MM; Møller JK; Schrøder H
Pediatr Blood Cancer; 2013 Aug; 60(8):1292-8. PubMed ID: 23417891
[TBL] [Abstract][Full Text] [Related]
13. The best solution down the line: an observational study on taurolidine- versus citrate-based lock solutions for central venous catheters in hemodialysis patients.
van Roeden S; van Oevelen M; Abrahams AC; Dekker FW; Rotmans JI; Meijvis SCA;
BMC Nephrol; 2021 Sep; 22(1):308. PubMed ID: 34517829
[TBL] [Abstract][Full Text] [Related]
14. Observational study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurolidine-citrate and heparin catheter locks in patients treated with hemodialysis.
Solomon LR; Cheesbrough JS; Bhargava R; Mitsides N; Heap M; Green G; Diggle P
Semin Dial; 2012; 25(2):233-8. PubMed ID: 21916999
[TBL] [Abstract][Full Text] [Related]
15. Taurolidine-citrate-heparin catheter lock solution reduces staphylococcal bacteraemia rates in haemodialysis patients.
Murray EC; Deighan C; Geddes C; Thomson PC
QJM; 2014 Dec; 107(12):995-1000. PubMed ID: 24939191
[TBL] [Abstract][Full Text] [Related]
16. A Taurolidine-Citrate-Heparin Lock Solution Effectively Eradicates Pathogens From the Catheter Biofilm in Hemodialysis Patients.
Zwiech R; Adelt M; Chrul S
Am J Ther; 2016; 23(2):e363-8. PubMed ID: 23665885
[TBL] [Abstract][Full Text] [Related]
17. Cefazolin-gentamicin versus taurolidine-citrate for the prevention of infection in tunneled central catheters in hemodialysis patients: A quasi-experimental trial.
Bueloni TNV; Marchi D; Caetano C; de Souza Cavalcante R; Mendes Amaral ML; Ponce D
Int J Infect Dis; 2019 Aug; 85():16-21. PubMed ID: 31102823
[TBL] [Abstract][Full Text] [Related]
18. Taurolidine lock is superior to heparin lock in the prevention of catheter related bloodstream infections and occlusions.
Olthof ED; Versleijen MW; Huisman-de Waal G; Feuth T; Kievit W; Wanten GJ
PLoS One; 2014; 9(11):e111216. PubMed ID: 25379781
[TBL] [Abstract][Full Text] [Related]
19. Taurolidine/Citrate Lock Therapy for Primary Prevention of Catheter-Related Infections in Cancer Patients: Results of a Prospective, Randomized, Phase IV Trial (ATAPAC).
Longo R; Llorens M; Goetz C; Platini C; Eid N; Sellies J; Ouamara N; Quétin P
Oncology; 2017; 93(2):99-105. PubMed ID: 28463827
[TBL] [Abstract][Full Text] [Related]
20. Taurolidine lock solution in the secondary prevention of central venous catheter-associated bloodstream infection in home parenteral nutrition patients.
Touré A; Lauverjat M; Peraldi C; Boncompain-Gerard M; Gelas P; Barnoud D; Chambrier C
Clin Nutr; 2012 Aug; 31(4):567-70. PubMed ID: 22285029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
